Valeant Pharmaceuticals (VRX) PT to $285 at BMO Capital Following 'Strong and Clean' Quarter
Tweet Send to a Friend
BMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE